EcoDrugPlus

Solute Carrier Family 6 Member 1

Ensembl ID : ENSACLG00000017076
Gene Symbol: SLC6A1
3 Cross references
208 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSACLG00000016437
Gene Symbol: SLC6A2
3 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSACLG00000016313
Gene Symbol: SLC6A3
3 Cross references
167 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSACLG00000009325
Gene Symbol: SLC6A4
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSACLG00000021317
Gene Symbol: SLC6A9
1 Cross references
207 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSACLG00000002050
Gene Symbol: SLC9A3
1 Cross references
226 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSACLG00000003211
Gene Symbol: SLC9A3
3 Cross references
226 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSACLG00000002443
Gene Symbol: SLC9A3
1 Cross references
223 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSACLG00000021162
Gene Symbol: SSTR2
3 Cross references
192 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSACLG00000025816
Gene Symbol: SSTR2
3 Cross references
192 Possible Orthologues:

Somatostatin Receptor 3

Ensembl ID : ENSACLG00000008032
Gene Symbol: SSTR3
2 Cross references
179 Possible Orthologues:

Somatostatin Receptor 5

Ensembl ID : ENSACLG00000021160
Gene Symbol: SSTR5
3 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).